The strong beat and guidance raise confirm accelerating operational momentum and deleveraging. Watch for continued debt paydown and potential upside to revenue guidance if growth trends persist.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $10.92entry
- T+1 · 6mo ago −2.47%α −2.14% · $10.65
- T+5 · 6mo ago −7.14%α −8.27% · $10.14
- T+20 · 6mo ago −21.70%α −24.48% · $8.55
- T+60 · 4mo ago +20.60%α +18.54% · $13.17
Price Chart
How similar events traded
Executive Summary
Bioventus reported Q1 2026 revenue of $132.1M (+7% YoY) and GAAP EPS of $0.04, swinging from a -$0.04 loss in the prior year. Non-GAAP EPS of $0.15 beat the $0.07 consensus by 114%, driven by revenue growth, margin expansion, and lower interest expense. The company raised full-year 2026 adjusted EPS guidance to $0.75-$0.79 and cash from operations guidance to $84M-$89M, while reaffirming revenue guidance of $600M-$610M.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $132.1M, +7% YoY, above $129.9M consensus
- GAAP EPS $0.04 vs -$0.04 YoY; Non-GAAP EPS $0.15 vs $0.08 YoY
- Non-GAAP EPS of $0.15 beat consensus estimate of $0.07 by 114%
- Adjusted EBITDA $23.9M, +24% YoY; operating cash flow $8.9M vs -$19.3M YoY
- Raised FY2026 adjusted EPS guidance to $0.75-$0.79 (from $0.73-$0.77) and cash from operations to $84M-$89M (from $82M-$87M)
- Reaffirmed FY2026 revenue guidance of $600M-$610M (+6-7% growth)
- Made $22M discretionary principal prepayment on term loan in March 2026
- Pain Treatments revenue +7.7%, Surgical Solutions +6.2%, Restorative Therapies +4.6%
Financial Impact
Q1 revenue beat by $2.2M vs consensus; Non-GAAP EPS beat by $0.08 vs consensus; raised FY guidance by $0.02 on EPS and $2M on cash from operations
Risk Factors
- Revenue guidance unchanged despite Q1 beat, implies deceleration in remaining quarters
- One-time $4.2M favorable rebate benefit in Pain Treatments may not repeat
- Debt still elevated at $272M despite $22M prepayment; interest expense remains a drag
- Tariff and regulatory risks cited in forward-looking statements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288701 |
Track record
18 reports on BVS
1 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 2 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $10.95 Now $10.46 −4.43% settles Feb 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
- Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 No price data
- Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
- Jun 2, 202623w ago Press Release Bearish 6/10 Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers